Cosmo Pharmaceuticals N.V.
COPN.SWDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Rifamycin SV MMX
Traveler's Diarrhea
Methylene Blue MMX®
Colorectal Cancer
400 mg Rifamycin SV dosage
Infectious Diarrhoea
Rifamycin SV 600mg t.i.d.
Diarrhea-predominant Irritable Bowel Syndrome
Methylene Blue MMX tablets
Colorectal Cancer
Methylene Blue MMX 25 mg modified release tablets
Colon Staining in Preparation for Colonoscopy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rifamycin SV MMX | Phase 3 | Traveler's Diarrhea | - | - |
Methylene Blue MMX® | Phase 3 | Colorectal Cancer | - | - |
400 mg Rifamycin SV dosage | Phase 2 | Infectious Diarrhoea | - | - |
Rifamycin SV 600mg t.i.d. | Phase 2 | Diarrhea-predominant Irritable Bowel Syndrome | - | - |
Methylene Blue MMX tablets | Phase 2 | Colorectal Cancer | - | - |
Methylene Blue MMX 25 mg modified release tablets | Phase 2 | Colon Staining in Preparation for Colonoscopy | - | - |
Frequently asked questions
What is in Cosmo Pharmaceuticals N.V.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Cosmo Pharmaceuticals N.V.'s (COPN.SW) pipeline across Phase 3, Phase 2. Its lead program is Rifamycin SV MMX (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cosmo Pharmaceuticals N.V.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Cosmo Pharmaceuticals N.V. (COPN.SW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track COPN.SW biotech catalysts?→
Add COPN.SW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cosmo Pharmaceuticals N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.